Members of our team had the opportunity to present a new poster abstract at AMCP 2026, which was held from April 13-16, 2026.
Authors
Andrew Wash, PharmD PhD; Chris Tomaino, PharmD; Erin Waters, PharmD; Jenna Daley, CPhT; Ana Lopez medina, PharmD, PhD; Casey Fitzpatrick, PharmD; Alesia Sypniewski, PharmD; Nicolina Castilla, PharmD
Background
-
Nearly three-quarters of U.S. adults are overweight or obese, creating a critical need for effective weight management strategies.1
-
Pharmacologic therapies, including GLP-1 and GIP/GLP-1 receptor agonists, are valuable tools, though access challenges such as medication shortages, limited insurance coverage, and high out-of-pocket costs persist.2,3
-
Health-system specialty pharmacy (HSSP) teams are well positioned to support patients through medication management and clinical monitoring.
Objectives
To evaluate medication access and clinical outcomes among patients enrolled in an HSSP-led chronic disease management (CDM) program for weight loss.
-
1
Overweight & obesity statistics. National Institute of Diabetes and Digestive and Kidney Diseases. Reviewed September 2021. Accessed March 4, 2026. https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity
-
2
Whitley HP, Trujillo JM, Neumiller JJ. Special report: potential strategies for addressing GLP-1 and dual GLP-1/GIp receptor agonist shortages. Clin Diabetes Publ Am Diabetes Assoc. 2023;41(3):467-473. doi:10.2337/cd23-0023
-
3
Gomez Lumbreras A, Tan MS, Villa-Zapata L, Ilham S, Earl JC, Malone DC. Cost-effectiveness analysis of five anti-obesity medications from a US payer'sperspective. Nutr Metab Cardiovasc Dis. 2023;33(6):1268-1276. doi:10.1016/j.numecd.2023.03.012
